Side Effects Don't Scare Icahn

By Brian Orelli, Ph.D. | More Articles
September 15, 2008 | Comments (1)

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Doesn't look like billionaire Carl Icahn is worried about the recently reported pancreatitis cases from Amylin Pharmaceuticals' (Nasdaq: AMLN ) Byetta. The investor upped his stake in the drug company by almost 50% and now owns 7.3% of the company.

Icahn obviously sees value in the company at these fire-sale prices and realizes that when investors panic is often the best time to invest.

We haven't heard much from Icahn about what his plans are for Amylin since he took a stake in the company back in May. Then again, the Investor of the Year nominee has been a little busy between failing to get Yahoo! (Nasdaq: YHOO ) and Biogen Idec (Nasdaq: BIIB ) sold off and now having to deal with ImClone Systems (Nasdaq: IMCL ) being bid on by Bristol-Myers Squibb (NYSE: BMY ) . It's understandable that Icahn might not want to get into a fight with management at this point.

When he does finally get around to dealing with Amylin, I think it's more likely that Icahn will try and shake up management rather than trying to get Amylin sold. With Amylin's major drug Byetta and its once-weekly successor already partnered up with Eli Lilly (NYSE: LLY ) , it could be hard to get a bidding war going. Then again, ImClone is partnered with Bristol-Myers and Icahn was able to find a mystery bidder to stir the pot, so maybe he can pull another rabbit out of the hat for Amylin as well.

Investors seem to be following Icahn's lead today and have sent the stock up more than 5% on a day when almost everything else is tanking. Call me the eternal optimist, but now may be the perfect time to be greedy.

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Biogen Idec is a Stock Advisor recommendation. Eli Lilly is an Income Investor pick. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., likes it when billionaires agree with him. He doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Report this Comment On September 15, 2008, at 4:11 PM, nielej wrote:

what does Icahn think of WCI filing for bankruptcy?

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 727898, ~/Articles/ArticleHandler.aspx, 2/14/2012 2:01:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
	DOW	12,874.04	72.81	0.57%
	S&P 500	1,351.77	9.13	0.68%
	NASD	2,931.39	27.51	0.95%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes